Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI
Traumatic Brain Injury
About this trial
This is an interventional treatment trial for Traumatic Brain Injury focused on measuring TBI, Virtual Reality
Eligibility Criteria
Inclusion Criteria:
- Male or female military health care beneficiaries 18-67 years of age;
- Presence of TBI (based on standard Veterans Affairs (VA)/ Department of Defense (DoD) criteria);
- With or without upper extremity dysfunction. Upper extremity dysfunction includes but is not limited to decreased coordination, increased tone, decreased strength, and decreased sensation;
- Ability to follow study instructions and likely to complete all required visits for the study;
- Ability to understand spoken and written English;
- At least 6 weeks post TBI.
Exclusion Criteria:
- Age less than 18 or greater than 67;
- Blind or otherwise visually impaired to the extent that lack of sight inhibits utilizing the system;
- Deafness;
- Inability to understand or comprehend consenting to the study;
- Active psychosis, suicidal or homicidal ideations or frequent violent episodes;
- Currently enrolled in active substance abuse treatment
- Inability to even minimally operate BBVR controllers.
Sites / Locations
- Walter Reed National Military Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Active Treatment Group
Wait-List Control Group
Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.